A61K - Preparations for medical, dental, or toilet purposes

More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)

Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
12/2004
12/02/2004	US20040242597 Combination
12/02/2004	US20040242578 Pyrimidineamines as angiogenesis modulators
12/02/2004	US20040242568 Dipeptidyl peptidase inhibitors
12/02/2004	US20040242566 Dipeptidyl peptidase inhibitors
12/02/2004	US20040242536 controlled-release mixtures of plant extracts, gelation polymers and drugs such as ximelagatran, used for prophylaxis of cardiovascular disorders
12/02/2004	US20040242498 CXCR3 antagonists
12/02/2004	US20040242490 CLK-peptide and SLK-peptide
12/02/2004	US20040241856 Using hematopoietic stem cell inhibition polypeptide to control differentiation of progenitor cells; for use in tissue engineering, bone marrow transplantation and tumor therapeutics
12/02/2004	US20040241714 Methods of assessment of drug metabolizing enzymes
12/02/2004	US20040241192 Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits
12/02/2004	US20040241187 An inactivated, disrupted influenza virus preparation of a hemagglutinin antigen stabilised by alpha-tocopherol succinate in the absence of thiomersal or at low levels of thiomersal; hemagglutinin detectable by a single radial immunoassay (SRID); mercury-free preservative; administering by any route
12/02/2004	US20040241183 Human lymphocyte vaccine adjuvant
12/02/2004	US20040241131 Compositions containing malonate salts in preventing in-grown hair arising from shaving
12/02/2004	US20040241088 Method for evaluating the efficacy of certain cancer treatments
12/02/2004	DE10308353A1 Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Diarylcycloalkylderivate, processes for their preparation and their use as medicaments
12/02/2004	CA2528521A1 Disease prevention and vaccination prior to thymic reactivations
12/02/2004	CA2526212A1 Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
12/02/2004	CA2525892A1 Apparatus and method for the treatment of infectious disease in keratinized tissue
12/02/2004	CA2525804A1 Use of chondroitinase abc enzyme for the treatment of cns injuries
12/02/2004	CA2525771A1 Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
12/02/2004	CA2525571A1 Compositions of a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to thecentral nervous system
12/02/2004	CA2524936A1 Compositions and methods for the preparation of human growth hormone glycosylation mutants
12/02/2004	CA2524867A1 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
12/02/2004	CA2524818A1 Protein kinase c peptides for use in withdrawal
12/02/2004	CA2524531A1 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/02/2004	CA2524047A1 Immunosuppressant compounds and compositions
12/02/2004	CA2523467A1 Treatment of t-cell mediated diseases
12/02/2004	CA2521575A1 Antibiotic composition
12/01/2004	EP1481992A2 Humanized antibodies that sequester amyloid beta peptide
12/01/2004	EP1481989A1 A-33 related antigens and their pharmacological uses
12/01/2004	EP1481667A1 NEP inhibitors for the treatment of female sexual dysfunction
12/01/2004	EP1480975A2 Chemical compounds
12/01/2004	EP1480948A1 Semicarbazide derivatives and their use as antithrombotics
12/01/2004	EP1480679A1 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
12/01/2004	EP1257584B9 Humanized antibodies that sequester amyloid beta peptide
12/01/2004	EP0625905B1 Composition containing body activated fragrance for contacting the skin and method of use
12/01/2004	CN1551885A Cyclic indole and heteroindole derivatives, the production and use thereof as medicaments
12/01/2004	CN1551872A Biologically active methylene blue derivatives
12/01/2004	CN1551767A Cancer treatment
12/01/2004	CN1551762A Valproic acid derivatives for the treatment of pain.
12/01/2004	CN1551728A Production of transduced hematopoietic progenitor cells
12/01/2004	CN1177614C Slow releasing composition
12/01/2004	CN1177613C Chemokine receptor antagonist and ocyclosporin in combined therapy
12/01/2004	CN1177582C Pharmaceutical aerosol compsn. contg. HFA227 and HFA 134a
11/2004
11/30/2004	CA2075189C Method and compositions for the synthesis of bch-189 and related compounds
11/25/2004	WO2004100960A2 Anti-inflammatory phosphonate compounds
11/25/2004	WO2004100899A2 Use of secretin in treatments of disorders associated with the amygdala
11/25/2004	WO2004100898A2 Therapeutic use of anti-cs1 antibodies
11/25/2004	WO2004100895A2 Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
11/25/2004	WO2004100893A2 Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
11/25/2004	WO2004100892A2 Novel fibroblast growth factors and methods of use thereof
11/25/2004	WO2004100891A2 Cytotoxic indeno and isoindoloisoquinolones
11/25/2004	WO2004100890A2 Rage g82s-related methods and compositions for treating inflammatory disorders
11/25/2004	WO2004100886A2 POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-kB PATHWAY
11/25/2004	WO2004100885A2 Compositions and methods for treating cancer
11/25/2004	WO2004100884A2 Oral care methods and products
11/25/2004	WO2004100883A2 Method for preparing thermoformed compositions containing acrylic polymer binders, pharmaceutual dosage forms and methods of preparing the same
11/25/2004	WO2004100882A2 Inhibition of drug binding to serum albumin
11/25/2004	WO2004100880A2 Controlled release formulation of erythromycin derivatives
11/25/2004	WO2004100878A2 Method of treatment of hemorrhagic disease using a factor viia/tissue factor inhibitor
11/25/2004	WO2004100877A2 Vaccine accelerator factor (vaf) for poultry
11/25/2004	WO2004100875A2 Benzimidazoles, compositions containing such compounds and methods of use
11/25/2004	WO2004100874A2 Androgen receptor modulators and methods of use thereof
11/25/2004	WO2004100873A2 Compounds, compositions, and methods
11/25/2004	WO2004100871A2 Combination of an aldosterone receptor antagonist and a renin inhibitor
11/25/2004	WO2004100870A2 Compositions and methods for wt1 specific immunotherapy
11/25/2004	WO2004100868A2 Method of treating transplant rejection
11/25/2004	WO2004100865A2 New benzimidazole derivatives
11/25/2004	WO2004100864A2 Treatment kit which assists with antibiotic therapy for intracellular infectious diseases
11/25/2004	WO2004100863A2 Composition for preventing and treatment of asthma comprising alpha-lipoic acid as an effective component
11/25/2004	WO2004100861A2 Pharmaceutical composition comprising lectin
11/25/2004	WO2004100860A2 Stable liposomes for microencapsulation of animal venoms
11/25/2004	WO2004091511A3 Compositions and methods to diagnose and treat lung cancer
11/25/2004	WO2004084842A3 Inhibitors of cathepsin s
11/25/2004	WO2004082615A3 A process for preparing sustained release tablets
11/25/2004	WO2004080399A3 Rapidly absorbing lipophilic skin compositions and uses therefor
11/25/2004	WO2004080395A3 Methods and compositions for cancer treatment
11/25/2004	WO2004078123A3 Early prostate cancer antigens (epca), polynucleotide sequences encoding them, and their use
11/25/2004	WO2004075831A3 Pharmacodynamic assay for inhibitors of 11-beta-hydroxysteroid dehydrogenase activity in animal tissues
11/25/2004	WO2004073646A3 Treatment of pain through expression of opioid receptors
11/25/2004	WO2004073637A3 Compositions comprising a defined polysaccharide component
11/25/2004	WO2004073611A3 Compounds for the treatment of metabolic disorders
11/25/2004	WO2004073610A3 Estrogen receptor modulators
11/25/2004	WO2004071443A3 Methods and compositions for modulating stem cells
11/25/2004	WO2004071433A3 Methods of treating disease
11/25/2004	WO2004071416B1 Novel inhibitors of formation of advanced glycation endproducts (ages)
11/25/2004	WO2004069204A3 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
11/25/2004	WO2004064781A3 Anti-inflammatory substituted phenols and elastomeric compositions for oral delivery of drugs
11/25/2004	WO2004062629A3 Apoptolidin analogs and derivatives for inducing apoptosis in transformed cells
11/25/2004	WO2004062620A3 Paricalcitol as a chemotherapeutic agent
11/25/2004	WO2004062606A3 Method of achieving accelerated fat loss by administration of a fat loss accelerating agent to a dieting mammal
11/25/2004	WO2004060298A3 Fast dissolving films for oral administration of drugs
11/25/2004	WO2004043379A3 Chemical compounds
11/25/2004	WO2004034972A3 Compounds, compositions, and methods
11/25/2004	US20040235920 Novel use of substituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders
11/25/2004	US20040235909 substituted bis/thiohydrazide amide compound; synergistic effect with taxol or taxotere, anticancer agents, side effect reduction
11/25/2004	US20040235898 pyridinium salts such as 1-ethyl-(E,E)-2,6-bis[2-[4-(dimethylamino)phenyl]ethenyl]pyridinium chloride, used as fungicides, bactericides or insecticides on substrates
11/25/2004	US20040235894 N-[[4-(2-Chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl benzenesulfonamide, used for prophylaxis of asthma and/or rhinitis; respiratory system disorders
11/25/2004	US20040235836 Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents
11/25/2004	US20040235835 For prophylaxis of of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis

1 ... 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 ... 295